Monoclonal Antibody Therapies
Total Trials
1
As Lead Sponsor
0
As Collaborator
Total Enrollment
33
NCT03957915
Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia
Phase: Early Phase 1
Role: Collaborator
Start: May 29, 2020
Completion: Feb 24, 2025
Loading map...